GlassScriptPhysician profile
Rebecca Yee
NPI 1043208689
$3,477.05
in general payments reported to CMS, 2019-2025
34 companies · $650 in 2025
The $650 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $310 · 2021: $646 · 2022: $722 · 2023: $423 · 2024: $162 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $477.24 | 2019-2025 | Liletta |
| Mayne Pharma Commercial LLC | $300.65 | 2021-2025 | |
| Hologic Sales and Service, LLC | $278.09 | 2019-2025 | Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $275.25 | 2019-2022 | |
| Coopersurgical, INC. | $242.43 | 2019-2025 | Paragard T 380a, Endosee |
| Organon LLC | $241.96 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $214.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $163.79 | 2019-2021 | |
| Amgen INC. | $154.83 | 2019-2022 | |
| Intuitive Surgical, INC. | $131.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.88 | 2019-2021 | |
| Exeltis, USA INC. | $91.35 | 2019-2025 | Slynd |
| Biogen, INC. | $84.29 | 2025 | Zurzuvae |
| Pfizer INC. | $77.08 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $67.24 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $59.28 | 2023-2025 | Veozah |
| Ascend Therapeutics US, LLC | $54.79 | 2021-2022 | |
| Mycovia Pharmaceuticals, INC. | $54.46 | 2023 | Vivjoa |
| Mylan Pharmaceuticals INC. | $46.84 | 2021 | |
| Myovant Sciences INC. | $43.43 | 2021 | |
| Roche Diagnostics Corporation | $39.04 | 2019 | |
| Sage Therapeutics, LLC | $30.07 | 2022 | |
| Evofem Biosciences, INC. | $27.16 | 2021 | |
| Lupin INC. | $26.97 | 2019 | |
| Avanos Medical | $25.08 | 2022 | |
| Shield Therapeutics INC | $24.63 | 2023 | Accrufer |
| Sanofi Pasteur INC. | $23.91 | 2023 | |
| Lilly USA, LLC | $23.52 | 2025 | Zepbound, Mounjaro |
| Olympus America INC. | $22.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.69 | 2022 | |
| Ethicon US, LLC | $17.99 | 2022 | |
| Aspira Women'S Health INC | $16.87 | 2019 | |
| Dilon Technologies, INC. | $13.00 | 2023 | Hemoblast Bellows |
| Channel Medsystems, INC. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.